Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine, EMD To Co-Develop Protein Multiplex Assays for xMAP

NEW YORK (GenomeWeb News) - Rules-Based Medicine and EMD Chemicals said today that they are partnering to develop and distribute immunoassay products for use on Luminex’s xMAP platform.
 
Under the terms of the agreement, biomarker testing firm RBM is providing EMD, a subsidiary of Germany’s Merck KGaA, exclusive distribution rights to its catalog of quantitative protein multiplex assays.
 
EMD will market RBM’s testing content in co-branded multi-analyte kits under its Novagen brand.
 
The kits will be available in the middle of 2008 and will be marketed to pharmaceutical and biotechnology companies and universities.
 
The agreement follows EMD’s announcement last week that it had signed a deal with Luminex to use the xMAP platform for multiplex immunoassays.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.